Brief: Cogent Biosciences Announces Positive Updated Lead-In Data From Ongoing Phase 3 Peak Trial Evaluating Bezuclastinib In Combination With Sunitinib In Patients With GIST

Cogent Biosciences

23/05/2024 23:51

May 23 (Reuters) - Cogent Biosciences Inc  COGT.O :
    * COGENT BIOSCIENCES ANNOUNCES POSITIVE UPDATED LEAD-IN DATA
FROM
ONGOING PHASE 3 PEAK TRIAL EVALUATING BEZUCLASTINIB IN
COMBINATION WITH SUNITINIB IN PATIENTS WITH GASTROINTESTINAL
STROMAL TUMORS (GIST) AT ASCO ANNUAL MEETING
    * COGENT BIOSCIENCES INC - PEAK PHASE 3 GUIDANCE ACCELERATED
WITH
ENROLLMENT COMPLETION NOW EXPECTED IN 3Q 2024
    * COGENT BIOSCIENCES- ANNOUNCES NEW ADVANCED GIST CLINICAL
TRIAL
SPONSORED BY SARC IN COLLABORATION WITH LIFE RAFT GROUP &
DANA-FARBER CANCER INSTITUTE
    * COGENT BIOSCIENCES INC - ADDITION OF BEZUCLASTINIB TO
SUNITINIB
CONTINUES TO BE GENERALLY WELL-TOLERATED WITH AN ENCOURAGING
SAFETY PROFILE

Source text for Eikon:  ID:nGNX3dJjd0 
Further company coverage:  COGT.O 

 ((Reuters.Briefs@thomsonreuters.com;))